New developments in topical psoriasis therapy

Mild-to-Moderate Psoriasis, Second Edition

Volumn , Issue , 2008, Pages 165-181

  Colaco, Shanthi M ^a   Fitzmaurice, Sarah ^b   Becker, Emily ^b   Cheung, Lawrence C C ^b   Koo, John Y M ^b   Lee, Chai Sue ^c   Sivanesan, Priya ^d   Malick, Farah ^e   Letsinger, Julie A ^f  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042265534     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (33)

1. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197:31-36.
2. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59(3):455-463.
3. van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197:326-334.
4. Warner Chilcott. Taclonex scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064%) pamphlet insert, May 2008.
5. Al Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42:796-802.
6. Galderma. Clobex spray (clobetasol propionate 0.05%) pamphlet insert, September 2006.
7. Data on file, Galderma Laboratories, L.P.
8. Koo JYM, Menter A, Feldman SR, et al. The COBRA Trial: A large-scale community-based trial on moderate and severe psoriasis. Cutis 2007; 80(suppl 5):3-40.
9. Connetics Corporation. Clobetasol propionate (foam) prescribing information. Palo Alto, CA: Connetics Corporation, January 2003.
10. Stoughton RB, Wullich K. Relation of application time to bioactivity of apotent topical glucocorticoid formulation. J Am Acad Dermatol 1990; 22:1038-1041.
11. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatol Treat 2005; 16:31-36.
12. Shore RN. Clearing of psoriatic lesions after the application of tape. N Engl J Med 1985; 312:246.
13. Shore RN. Treatment of psoriasis with prolonged application of tape. J Am Acad Dermatol 1986; 15:540-542.
14. Volden G, Kragballe K, van De Kerkhof PC, et al. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat 2001; 12:141-144.
15. van de Kerkhof PC, Chang A, van der Walle HB, et al. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta dermato-venereologica 1994; 74:143-146.
16. van Vlijmen-Willems IM, Chang A, Boezeman JB, et al. The immunohistochemical effect of a hydrocolloid occlusive dressing (DuoDERM E) in psoriasis vulgaris. Dermatology (Basel, Switzerland) 1993; 187:257-262.
17. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta dermato-venereologica 1992; 72:69-71.
18. Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone ace-tonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta dermato-venereologica 1991; 71:540-542.
19. Wilkinson RD, Ohayon M. Therapeutic response to a dermatologic patch and betamethasone valerate 0.1 percent cream in the management of chronic plaques in psoriasis. Cutis 1990; 45:468-470.
20. Gottlieb AB, Staiano-Coico L, Cohen SR, et al. Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques. J Dermatol Sci 1990; 1:93-96.
21. A trial of the Actiderm dermatological patch and topical corticosteroids in the treatment of psoriasis vulgaris. The Actiderm Multi-Center Study Group. Cutis 1990; 46:84-88.
22. Juhlin L. Treatment of psoriasis and other dermatoses with a single application of a corticosteroid left under a hydrocolloid occlusive dressing for one week. Acta dermato-venereologica 1989; 69:355-357.
23. David M, Lowe NJ. Psoriasis therapy: Comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989; 21:511-514.
24. Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987; 123:1046-1052.
25. Hwang SM, Ahn SK, Menon GK, et al. Basis of occlusive therapy in psoriasis: Correcting defects in permeability barrier and calcium gradient. Int J Dermatol 2001; 40:223-231.
26. Fry L, Almeyda J, McMinn RM. Effect of plastic occlusive dressings on psoriatic epidermis. Br J Dermatol 1970; 82:458-462.
27. Fisher LB, Maibach HI. Physical occlusion controlling epidermal mitosis. J Invest Dermatol 1972; 59:106-108.
28. Rovee DT, Kurowsky CA, Labun J. Local wound environment and epidermal healing. Mitotic response. Arch Dermatol 1972; 106:330-334.
29. Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte cohesion, and alpha hydroxy acids. J Am Acad Dermatol 1984; 11:867-879.
30. Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician 1990; 41:1531-1538.
31. Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9:2.
32. Zaghloul SS, Good?eld JJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140(4):408-414.
33. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137(3):280-284.